UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma

Liver international, 2017-01, Vol.37 (S1), p.136-139

2017

Volltextzugriff (PDF)

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma

Hepatology (Baltimore, Md.), 2008-01, Vol.47 (1), p.97-104

2008

Volltextzugriff (PDF)

Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues

Cancer research (Chicago, Ill.), 2019-10, Vol.79 (20), p.5167-5180

2019

Volltextzugriff (PDF)

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma

Gut, 2012-10, Vol.61 (10), p.1481-1487

2012

Volltextzugriff (PDF)

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

Viruses, 2019-05, Vol.11 (5), p.406

2019

Volltextzugriff (PDF)

OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1

Cellular and molecular life sciences : CMLS, 2021-12, Vol.78 (23), p.7505-7518

2021

Volltextzugriff (PDF)

Identification of Dhx15 as a Major Regulator of Liver Development, Regeneration, and Tumor Growth in Zebrafish and Mice

International journal of molecular sciences, 2024-04, Vol.25 (7), p.3716

2024

Volltextzugriff (PDF)

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

Frontiers in immunology, 2024-05, Vol.15, p.1400553

2024

Volltextzugriff (PDF)

Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

Biomedicine & pharmacotherapy, 2024-01, Vol.170, p.116038-116038, Article 116038

2024

Volltextzugriff (PDF)

Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma

Cancers, 2024-04, Vol.16 (8), p.1491

2024

Volltextzugriff (PDF)

DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

Cancers, 2022-04, Vol.14 (9), p.2048

2022

Volltextzugriff (PDF)

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

Cancers, 2020-02, Vol.12 (2), p.332

2020

Volltextzugriff (PDF)

Real-time PCR improves Helicobacter pylori detection in patients with peptic ulcer bleeding

PloS one, 2011-05, Vol.6 (5), p.e20009-e20009

2011

Volltextzugriff (PDF)

miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

Cells (Basel, Switzerland), 2022-08, Vol.11 (17), p.2673

2022

Volltextzugriff (PDF)

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

Cancers, 2021-01, Vol.13 (3), p.426

2021

Volltextzugriff (PDF)

miRNA Expression and HCC Occurrence in HCV Cirrhotic Patients Treated with Direct Acting Antivirals

Livers, 2024-06, Vol.4 (2), p.275-286

2024

Volltextzugriff (PDF)

Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells

Biomarker research, 2024-04, Vol.12 (1), p.38-38, Article 38

2024

Volltextzugriff (PDF)

Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment

Gastrointestinal disorders (Basel, Switzerland), 2022-07, Vol.4 (3), p.141-152

2022

Volltextzugriff (PDF)

Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers

Hepatology (Baltimore, Md.), 2003-12, Vol.38 (6), p.1458-1467, Article ajhep09024

2003

Volltextzugriff (PDF)

MicroRNA Analysis for Outcome Prediction in Hepatitis B Virus–Related Liver Cancer

Gastroenterology (New York, N.Y. 1943), 2010-04, Vol.138 (4), p.1624-1626

2010

Volltextzugriff (PDF)

K-ras Mutations in DNA Extracted From the Plasma of Patients With Pancreatic Carcinoma: Diagnostic Utility and Prognostic Significance

Journal of clinical oncology, 1999-02, Vol.17 (2), p.578-584

1999

Volltextzugriff (PDF)

Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

Seminars in liver disease, 2017-05, Vol.37 (2), p.109

2017

Volltextzugriff (PDF)

FRI-494-YI Cabozantinib induces mtDNA-dependent cytotoxicity through cGas-STING signaling in experimental hepatocellular carcinoma

Journal of hepatology, 2024-06, Vol.80, p.S425-S426

2024

Volltextzugriff (PDF)

FRI-491-YI Targeting inflammasome activation by sorafenib/regorafenib as strategy to enhance efficacy in hepatocellular carcinoma therapy

Journal of hepatology, 2024-06, Vol.80, p.S424-S425

2024

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(71)
Mit Volltextzugriff
(76)

Publikationsform

Artikel
(77)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(51)
Life Sciences & Biomedicine
(50)
Humans
(37)
Gastroenterology & Hepatology
(24)
Male
(24)
Liver Cancer
(22)
Female
(21)
Hepatocellular Carcinoma
(21)
Biological And Medical Sciences
(20)
Medical Sciences
(19)
Middle Aged
(19)
Aged
(18)
Tumors
(17)
Oncology
(13)
Animals
(11)
Gastroenterology. Liver. Pancreas. Abdomen
(11)
Liver. Biliary Tract. Portal Circulation. Exocrine Pancreas
(10)
Carcinoma, Hepatocellular - Metabolism
(9)
Liver Neoplasms - Metabolism
(9)
Liver Neoplasms - Pathology
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

The impact of direct antiviral agents on the development and recurrence of hepatocellular carcinoma

Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma

Identification of Coding and Long Noncoding RNAs Differentially Expressed in Tumors and Preferentially Expressed in Healthy Tissues

Prospective validation of an immunohistochemical panel (glypican 3, heat shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma

Hepatocellular Carcinoma Recurrence in HCV Patients Treated with Direct Antiviral Agents

OncomiRs miR-106a and miR-17 negatively regulate the nucleoside-derived drug transporter hCNT1

Identification of Dhx15 as a Major Regulator of Liver Development, Regeneration, and Tumor Growth in Zebrafish and Mice

Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH

Sensitization of cholangiocarcinoma cells to chemotherapy through BCRP inhibition with β-caryophyllene oxide

Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

DNA Methylation Regulates a Set of Long Non-Coding RNAs Compromising Hepatic Identity during Hepatocarcinogenesis

Regorafenib Alteration of the BCL-xL/MCL-1 Ratio Provides a Therapeutic Opportunity for BH3-Mimetics in Hepatocellular Carcinoma Models

Real-time PCR improves Helicobacter pylori detection in patients with peptic ulcer bleeding

miR-200c-3p, miR-222-5p, and miR-512-3p Constitute a Biomarker Signature of Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma

Activated Lymphocytes and Increased Risk of Dermatologic Adverse Events during Sorafenib Therapy for Hepatocellular Carcinoma

miRNA Expression and HCC Occurrence in HCV Cirrhotic Patients Treated with Direct Acting Antivirals

Metallothionein-3 is a multifunctional driver that modulates the development of sorafenib-resistant phenotype in hepatocellular carcinoma cells

Low Baseline Plasma L-Glutamine Concentration Identifies Hepatocellular Carcinoma Patients at High Risk of Developing Early Gastrointestinal Adverse Events during Sorafenib Treatment

Hepatitis C virus and liver disease: Global transcriptional profiling and identification of potential markers

MicroRNA Analysis for Outcome Prediction in Hepatitis B Virus–Related Liver Cancer

K-ras Mutations in DNA Extracted From the Plasma of Patients With Pancreatic Carcinoma: Diagnostic Utility and Prognostic Significance

Liver Cancer Emergence Associated with Antiviral Treatment: An Immune Surveillance Failure?

FRI-494-YI Cabozantinib induces mtDNA-dependent cytotoxicity through cGas-STING signaling in experimental hepatocellular carcinoma

FRI-491-YI Targeting inflammasome activation by sorafenib/regorafenib as strategy to enhance efficacy in hepatocellular carcinoma therapy

Suchergebnisse filtern